In a new study, researchers have attacked cancer stem cells on two fronts: glycolysis and oxidative phosphorylation.
According to a new study published in the journal Cell Metabolism, it might be possible to attack cancer by exploiting its own cellular metabolism rather than by employing drugs to kill cancerous cells directly [1].
Study summary
Posted in biotech/medical, military, neuroscience
https://paper.li/e-1437691924#/
They have been called the main news channel internationally and have a wider range than CNN and Al Jazeera. They have also taken the right to broadcast the best documentary on the development of mind control as a major political program. The Spanish TV-producer Daniel Estulin made the 25 minute presentation and interviewed Magnus Olsson who presented examples of victims that can be subjected to life-destructive research without their consent. The introduction gives a picture from the 1960s CIA project MKULTRA with tens of thousands of victims and a research based on state crime, medical abuse and kept beyond public attention.
University hospitals in the United States and Europe were central places where patients were implanted, utilized and misused for a life time of brain research and experiments. That situation has a similar pattern internationally and was built in behind the military and intelligence agencys classified operations. In Sweden the military research institution FOI became the innovator, knowledge bank and educated professors and physicians in collaboration with hospitals where the project was given highest priority.
The documentary’s original language is Spanish but has got English subtitles to be shown world-wide. Daniel Estulin has by far made the strongest warning about the hidden techno-political development. Mr. Estulin is also one with the strength of the challenge and his presentation gives an expression that fits the crucial mission he proclaims. While interviewing people on the street of Madrid, both school children and adults show examples of the unknown technology and its use:”…I have never heard about it … It sounds too fantastic… Can it really be like that…” Something normal of a techno-political development hidden from media and the public.
Bizarre fossils from China are revealing our species’ Asian origins and rewriting the story of human evolution.
By Kate Douglas
DECEMBER 1941. Japan has just entered the second world war. China, already fighting its neighbour, is in the firing line. At the Peking Union Medical College Hospital, Hu Chengzhi carefully packs two wooden crates with the world’s most precious anthropological artefacts. Peking Man – in reality some 200 fossilised teeth and bones, including six skulls – is to be shipped to the US for safekeeping. This is the last anyone ever sees of him.
An exciting experimental drug developed by scientists at Johns Hopkins Medicine has been found to stop the progression of Parkinson’s disease in live mice models. The new drug could be the first medication to specifically slow the progression of the devastating disease as opposed to current treatments that only target the symptoms.
Microglia are a kind of immune cell primarily found in the brain. One of the neurodegenerative processes that occurs in the brains of Parkinson’s disease patients is when the microglial cells send chemical signals to another kind of brain cell called astrocytes. This signal spurns those astrocytes into more aggressive behaviors, eating away at connections between neurons.
“The activated astrocytes we focused on go into a revolt against the brain,” explains Ted Dawson, one of the researchers on the project, “and this structural breakdown contributes to the dead zones of brain tissue found in those with Parkinson’s disease. The idea was that if we could find a way to calm those astrocytes, we might be able to slow the progression of Parkinson’s disease.”
Researchers have manipulated the immune system to respond more aggressively to cancer according to a new study [1].
Manipulating macrophages
We have discussed modulating the immune system multiple times recently, especially in regards to macrophages and manipulating their behavior. Macrophages are part of the innate immune system and carry out a wide variety of tasks, such as clearing away cell debris, engulfing pathogens, facilitating tissue growth, and disposing of senescent cells once other immune cells have destroyed them.
British researchers are zeroing in on genes they believe are responsible for early onset Alzheimer’s disease in people with Down syndrome.
WEDNESDAY, July 3, 2018 — British researchers are zeroing in on the genes that they believe are responsible for early onset Alzheimer’s disease in people with Down syndrome.
The two conditions have long been strongly linked.
The findings — based on research with mice — could pave the way for new medicines to prevent Alzheimer’s in people with Down syndrome, and shed light on the development of dementia in the general population, the study authors said.
Following heart attacks, a handful of monkeys regained some of the pumping ability their hearts had lost after being given human embryonic stem cells, according to a study published Monday in Nature Biotechnology.
Scientists have tried for years to develop a stem cell treatment for heart disease caused by lack of blood flow, which contributed to more than 9.4 million deaths worldwide in 2016, according to the World Health Organization.
“We’re talking about the number one cause of death in the world [for humans],” said study author Dr. Charles Murry, director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington. “And at the moment all of our treatments are … dancing around the root problem, which is that you don’t have enough muscle cells.”
“I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses,” said FDA commissioner Dr Scott Gottlieb after Luxturna’s approval.
As innovative gene and cell therapies continue to make the transition from the laboratory to the clinic, they are bringing with them the promise of truly personalised medicine. The last few years have seen the regulatory approval of the first gene therapies that take a patient’s own immune cells and genetically engineer them to target cancer cells more effectively.
These chimeric antigen receptor T-cell (CAR-T) therapies now represent a rapidly growing field, with Novartis’s Kymriah, the first CAR-T therapy approved by the US Food and Drug Administration (FDA) in August 2017 for the treatment of a rare blood cancer, seen as the tip of the iceberg for this treatment class’ potential. Approval of Kite Pharma’s Yescarta, a CAR-T treatment for certain forms of non-Hodgkin lymphoma, followed just a few months later.
Scientists have designed a special type of drug that helps the body eat and destroy cancerous cells.
The treatment boosts the action of white blood cells, called macrophages, that the immune system uses to gobble up unwanted invaders.
Tests in mice showed the therapy worked for aggressive breast and skin tumours, Nature Biomedical Engineering journal reports.
